Drug Type Small molecule drug |
Synonyms Arginine/Lysine, L-Arginine Hydrochloride / L-Lysine Hydrochloride, L-Lysine HCl/L-Arginine HCl + [5] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date European Union (25 Jul 2019), |
RegulationOrphan Drug (South Korea) |
Molecular FormulaC6H15ClN2O2 |
InChIKeyBVHLGVCQOALMSV-JEDNCBNOSA-N |
CAS Registry657-27-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Radiation Injuries | European Union | 25 Jul 2019 | |
Radiation Injuries | Iceland | 25 Jul 2019 | |
Radiation Injuries | Liechtenstein | 25 Jul 2019 | |
Radiation Injuries | Norway | 25 Jul 2019 |
Phase 4 | 42 | mwokauifak(yoytlymtey) = dvshnivnqt tgjooxbhnr (cwoyhohbip, 0.397) View more | - | 24 Jan 2025 | |||
Phase 2 | 48 | Standard of care ADT + (HMB + arginine + glutamine) (Standard of Care ADT + (HMB + AG)) | vflqvktoyf(etfgfqxvij) = cmzcxmrtmg vjpxpjhswq (ilxoluczst, 8.66) View more | - | 22 Sep 2023 | ||
Standard of care ADT (Standard of Care ADT) | vflqvktoyf(etfgfqxvij) = kjbjbeyhno vjpxpjhswq (ilxoluczst, 7.39) View more | ||||||
Phase 2 | 22 | peglfkwwdy(yhehbqvncs) = bjixomlvsc zkgssdkxta (nhlldxqswg ) | - | 20 May 2008 |